Fig. 2

A The survival difference in progression-free survival (PFS) between different immune checkpoint inhibitor (ICI) combinations. B The survival difference in overall survival (OS) between different ICI combinations. C The survival difference in PFS between patients with exon 19 deletions and L858R mutations. D The survival difference in OS between patients with exon 19 deletions and L858R mutations. E The survival difference in PFS between T790M positive patients and T790M negative patients. F The survival difference in OS between T790M positive patients and T790M negative patients. G The survival difference in PFS between TP53 co-mutation patients and patients without a TP53 co-mutation. H The survival difference in OS between TP53 co-mutation patients and patients without a TP53 co-mutation. I The survival difference in PFS between TKI-PFS < 10 months and TKI-PFS > 10 months. J The survival difference in OS between TKI-PFS < 10 months and TKI-PFS > 10 months